Turka Laurence A. 4
4 · Rubius Therapeutics, Inc. · Filed Jan 31, 2023
Insider Transaction Report
Form 4
Turka Laurence A.
Chief Scientific Officer
Transactions
- Exercise/Conversion
Restricted Stock Units
2023-01-31−8,625→ 25,875 total→ Common Stock (8,625 underlying) - Exercise/Conversion
Common Stock
2023-01-29+7,438→ 12,359 total - Sale
Common Stock
2023-01-31$0.24/sh−2,593$622→ 18,391 total - Exercise/Conversion
Common Stock
2023-01-31+8,625→ 20,984 total - Exercise/Conversion
Restricted Stock Units
2023-01-29−7,438→ 14,874 total→ Common Stock (7,438 underlying)
Footnotes (4)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- [F2]Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units listed in Table II. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the reporting person.
- [F3]The shares underlying the restricted stock units vest in four equal annual installments beginning on January 29, 2022.
- [F4]The shares underlying the restricted stock units vest in four equal annual installments beginning on January 31, 2023.